PM
NBIX icon

Prosight Management’s Neurocrine Biosciences NBIX Stock Holding History

Prosight Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-62,000
Closed -$7.14M – 44
2024
Q3 		$7.14M Buy
62,000
+35,000
+130% +$4.8M 1.76% 21
2024
Q2 		$3.72M Sell
27,000
-3,500
-11% -$480K 1.11% 26
2024
Q1 		$4.21M Sell
30,500
-5,400
-15% -$737K 1.17% 24
2023
Q4 		$4.73M Sell
35,900
-44,100
-55% -$5.08M 1.9% 16
2023
Q3 		$9M Sell
80,000
-90,000
-53% -$9.48M 2.85% 11
2023
Q2 		$16M Buy
170,000
+90,000
+113% +$8.79M 4.69% 9
2023
Q1 		$8.1M Buy
+80,000
New +$8.32M 3.84% 11

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prosight Management's NBIX Position: Q4 2024 in Review

Prosight Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 62,000 shares — an estimated $7.14M sold.

Prosight Management first reported a position in NBIX in Q1 2023 and held it in 7 quarters. The position peaked at $16M in Q2 2023. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Prosight Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Prosight Management sold 62,000 Neurocrine Biosciences shares in Q4 2024, an estimated $7.14M.
  • Prosight Management first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 7 quarters.
  • Prosight Management's Neurocrine Biosciences position peaked at $16M in Q2 2023.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.